Examination of the Effect of Increasing Doses of Etoricoxib on Oral Methotrexate Pharmacokinetics in Patients with Rheumatoid Arthritis

Journal of Clinical Pharmacology

Volumn 49, Issue 10, 2009, Pages 1202-1209

  Schwartz, Jules I ^a   Agrawal, Nancy G B ^a   Wong, P H ^a   Miller, Jutta ^a   Bachmann, Kenneth ^b   Marbury, Thomas ^c   Hoelscher, David ^d   Cavanaugh Jr , Paul F ^a   Gottesdiener, Keith ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Center for Applied Pharmacology   (United States)

^c ORLANDO CLINICAL RESEARCH CENTER   (United States)

^d Pharmaceutical Product Development   (United States)

Author keywords

Etoricoxib; Methotrexate; Pharmacokinetics; Rheumatoid arthritis

Indexed keywords

ETORICOXIB; METHOTREXATE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; DRUG URINE LEVEL; FEMALE; HEADACHE; HUMAN; INSOMNIA; MALE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PYRIDINES; SULFONES;

EID: 70349515537     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009338939     Document Type: Article

References (24)

1. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002 ; 46: 328-346.
2. Borchers AT, Keen CL, Cheema GS, Gershwin ME The use of methotrexate in rheumatoid arthritis. Semin Arthritis Rheum. 2004 ; 34: 465-483.
3. Iqbal MP, Baig JA, Ali AA The effects of non-steroidal anti-inflammatory drugs on the disposition of methotrexate in patients with rheumatoid arthritis. Biopharm Drug Dispos. 1998 ; 19: 163-167.
4. Davies NM, Anderson KE Clinical pharmacokinetics of diclofenac. Clin Pharmacokinet. 1997 ; 33: 184-213.
5. Tracy TS, Worster T., Bradley JD Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbioprofen in patients with rheumatoid arthritis. Br J Clin Pharmacol. 1994 ; 37: 453-456.
6. Combe B., Edno L., Lafforgue P. Total and free methotrexate pharmacokinetics with and without piroxicam in rheumatoid arthritis patients. Br J Rheumatol. 1995 ; 34: 421-428.
7. Furst DE, Herman RA, Koehnke R., et al. Effect of aspirin and sulindac on methotrexate clearance. J Pharm Sci. 1990 ; 79: 782-786.
8. Furst DE Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br J Rheumatol. 1995 ; 34 (suppl 2). 20-25.
9. Ellison NM, Servi RJ Acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU: a possible adverse effect due to concomitant indomethacin administration. Cancer Treat Rep. 1985 ; 69: 342-343.
10. Thyss A., Milano G., Kubar J., Namer M., Schneider M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet. 1986 ; 1: 256-258.
11. Ng HW, Macfarlane AW, Graham RM, Verbov JL Near fatal drug interactions with methotrexate given for psoriasis. Br Med J (Clin Res Ed). 1987 ; 295: 752-753.
12. Singh RR, Malaviya AN, Pandey JN, Guleria JS Fatal interaction between methotrexate and naproxen. Lancet. 1986 ; 1: 1390.
13. Zuik M., Mandel MA Methotrexate-salicylate interaction: a clinical and experimental study. Surg Forum. 1975 ; 26: 567-569.
14. Maiche AG Acute renal failure due to concomitant action of methotrexate and indomethacin. Lancet. 1986 ; 1: 1390.
15. Daly HM, Scott GL, Boyle J, Roberts CJ. Methotrexate toxicity precipitated by azapropazone. Br J Dermatol. 1986;114:733-735
16. Matsumoto AK, Melian A, Mandel DR, et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol. 2002;29:1623-1630.
17. Collantes E., Curtis SP, Lee KW, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract. 2002 ; 3: 1-10.
18. Arcoxia [UK product insert, 60 mg, 90 mg, 120 mg film-coated tablets]. UK (Product circular). Whitehouse Station, NJ: Merck & Co, Inc ; 2002.
19. Rodrigues AD, Winchell GA, Dobrinska MR Use of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: the need for quantitative databases. J Clin Pharmacol. 2001 ; 41: 368-373.
20. Metropolitan height and weight tables. 1983 Stat Bull. 1983; 64: 3-9.
21. Cockcroft DW, Gault MH Prediction of creatinine clearance from serum creatinine. Nephron. 1976 ; 16: 31-41.
22. Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006 ; 368: 1771-1781.
23. Songsiridej N., Furst DE Methotrexate-the rapidly acting drug. Baillieres Clin Rheumatol. 1990 ; 4: 575-593.
24. Liegler DG, Henderson ES, Hahn MA, Oliverio VT The effect of organic acids on renal clearance of methotrexate in man. Clin Pharmacol Ther. 1969 ; 10: 849-857.